Monitor for initiation of the Phase 2b/3 trial as a near-term catalyst; insider buying may signal confidence but is not material to valuation without further clinical or funding updates.
Price Chart
Executive Summary
OKYO Pharma announced that Chief Development Officer and Director Gary Jacob acquired 30,980 additional shares at $1.59, increasing his total holding to 108,920 shares. The company also provided an update on its lead drug urcosimod, highlighting positive Phase 2a results in neuropathic corneal pain and plans for a Phase 2b/3 trial in the first half of 2026.
Key Facts
- Chief Development Officer Gary Jacob purchased 30,980 OKYO shares at $1.59 per share.
- His total ownership is now 108,920 ordinary shares.
- Urcosimod showed positive pain reduction results in a Phase 2a NCP trial with 18 subjects.
- A prior Phase 2 trial in dry eye disease (240 subjects) also showed significant pain reduction.
- OKYO plans to initiate a ~150-patient Phase 2b/3 trial for urcosimod in NCP in the first half of 2026.
Financial Impact
Insider purchase of $49,258 (30,980 shares × $1.59), minimal direct financial impact.
Risk Factors
- Clinical-stage biotech risk: urcosimod remains investigational with no guarantee of success in larger trials.
- Low trading volume and market cap increase volatility and susceptibility to dilution in future financings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258842 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.49 (+9.56%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.49 (−2.61%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.49 (−5.10%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.49 (−9.15%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.49 (−9.15%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers